跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT06802146
NCT06802146招募中1 期

A Multi-Site Break Through Cancer Pilot Study Testing the Feasibility and Safety of Therapeutic Intervention for Patients With High-risk Clonal Cytopenia of Undetermined Significance (CCUS)

Lachelle D. Weeks, MD, PhD2 个研究点 分布在 1 个国家目标入组 108 人开始时间: 2025年2月7日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
干预措施
相关药物

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
108
试验地点
2
主要终点
Feasibility Failure Rate (FFR)
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This research is being done to find out more about the potential risks and benefits of early treatment in participants with high risk Clonal Cytopenia of Unknown Significance (CCUS). This study will give eligible CCUS participants the option of either being observed or taking an oral drug as treatment.

The names of the study drug involved in this study is:

-Decitabine/cedazuridine (DEC/CED) (a nucleoside metabolic inhibitor and cytidine deaminase inhibitor).

详细描述

This is an open-label, multicenter pilot study testing the feasibility and safety of early pharmacologic intervention, decitabine/cedazuridine, in participants with higher-risk clonal cytopenia of unknown significance (CCUS).

The U.S. Food and Drug Administration (FDA) has not approved DEC/CED for CCUS but it has been approved for other uses.

The research study procedures include screening for eligibility, in-clinic treatment visits, electrocardiograms, echocardiograms, bone marrow biopsies, and blood tests.

Participants who choose to enroll in the intervention cohort will receive the oral drug for 1 year and will continue in a post-treatment observation period for 2 years after treatment. Participants in both groups will each participate in the study for 3 years total.

It is expected that the study will continue to enroll up to 108 participants in total or until there are 30 participants enrolled in the early intervention cohort, whichever occurs first.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •Age ≥18 years.
  • •Unexplained cytopenia(s) for at least 4 months (at least two separate labs within 4 months including at time of screening must meet this criteria). Cytopenia(s) defined as the presence of ≥ 1 of the following:
  • •Hemoglobin (Hgb) <12 g/dL for women and <13g/dL for men
  • •Absolute neutrophil count (ANC) < 1.8 × 109/L*
  • •Platelet count (Plt) <150 × 109/L *Patients known to have a Duffy-null genotype must have anemia (Hgb < 12g/dL for women, Hgb <13g/dL for men) and/or thrombocytopenia (Plt < 150 × 109/L) to be eligible for this study.
  • •1 pathogenic variant detected in any myeloid driver gene with a VAF of at least 0.02 (2%) identified by local next generation sequencing (NGS) of peripheral blood or bone marrow sample within 3 months from screening bone marrow biopsy.
  • •Participants must have a high risk score per the Clonal Hematopoiesis Risk Calculator (CHRS). See APPENDIX C for calculation.
  • •Screening bone marrow biopsy must not be diagnostic of any overt hematologic malignancy by morphologic assessment and must be consistent with a diagnosis of clonal cytopenia of unknown significance (CCUS) as determined by multi-institutional hematopathology review.
  • •ECOG performance status 0-2 (see Appendix A).
  • •Participants must meet the following organ function as defined below:
  • •Serum aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤3x upper limit of normal (ULN).
  • •Serum total bilirubin <1.5x ULN. Higher levels are acceptable if these can be attributed to ineffective erythropoiesis or Gilbert's syndrome. In these cases, approval from the study Sponsor-Investigator is required.
  • •Creatinine clearance greater than 40 mL/min based on the Cockcroft-Gault glomerular filtration rate estimation.
  • •Ability to understand and the willingness to sign a written informed consent document.
  • •For participants of the early pharmacologic intervention cohort: women of childbearing potential must use highly effective contraception during treatment for at least 6 months after the last dose and males with female partners of reproductive potential should use effective contraception during treatment and for 3 months after the last dose.

排除标准

  • •Concurrent primary malignancy requiring active cytotoxic chemotherapy and/or ionizing radiation therapy.
  • •Known inherited bone marrow failure disorder and/or germline predisposition to hematologic malignancy.
  • •Receipt of anti-cancer therapy including any cytotoxic chemotherapy, ionizing radiation therapy, immunomodulatory agents such as lenalidomide, and targeted anti-cancer therapies including PARP inhibitors within the last 6 months. Patients with complete surgical resection of a tumor are not excluded from this study.
  • •Anti-cancer therapy, including any cytotoxic chemotherapy, ionizing radiation therapy, immunomodulatory agents such as lenalidomide and targeted agents such as PARP inhibitors, planned in the next 6 months. Patients on hormonal adjuvant therapy for nonmetastatic breast and prostate cancer or other minimally-myelosuppressive maintenance therapies for non-metastatic cancer may be eligible at the discretion of the study PI.
  • •Diagnosis of MDS, MPN, CMML, AML or any other hematolymphoid malignancy in the patient's lifetime. This includes individuals with MDS-defining chromosomal abnormalities identified via conventional karyotype or FISH.
  • •Presence of a concurrent hematologic malignancy precursor state, such as smoldering multiple myeloma (SMM), and smoldering Waldenstrom's macroglobulinemia.
  • •Presence of an early-stage hematologic precursor state-such as monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B cell lymphocytosis (MBL).
  • •Active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment).
  • •Recent (within 3 months) vaccination with any live attenuated vaccine or vaccination with live attenuated vaccine planned during the next 15 months. *Live attenuated vaccines include measles, mumps, rubella (MMR combined vaccine), rotavirus, smallpox, chickenpox, and yellow fever.
  • •Laboratory evidence indicative of clinically significant red cell hemolysis.
  • •Hypersplenism and/or evidence of portal hypertension on physical exam or imaging.
  • •Pregnant or lactating.

研究组 & 干预措施

Inqovi Cohort

Experimental

Participants will be enrolled and will complete:

  • Baseline visit.
  • In-clinic visits with assessments: Cycle 1 days 8, 15, and 22.
  • In-clinic visits with assessments and bone marrow biopsies: Cycles 2 - 12 Day 1.
  • Cycle 1 - 12:

• Days 1 - 5 of 28 day cycle: Predetermined dose of Inqovi 1x daily.

  • End of Treatment visit, Cycle 13 Day 1, with assessments and bone marrow biopsy.
  • Follow up in-clinic visits with assessments: Cycle 19 Day 21, Cycle 25 Day 1, Cycle 31 Day 1, and Cycle 36 Day 28. Bone marrow biopsy at Cycle 25 Day 1.
  • End of Study visit, Cycle 36 Day 28, with assessments and bone marrow biopsy.

干预措施: Inqovi (Drug)

Observational Cohort

No Intervention

Participants will complete:

  • Baseline visit.
  • In-clinic visits with assessments: Cycle 7 Day 1, Cycle 13 Day, Cycle 19 Day, Cycle 25 Day 1, and Cycle 31 Day 1.
  • Bone marrow biopsies every 12 months at Cycle 13 Day 1 and Cycle 25 Day.
  • End of study visit, Cycle 36 Day 28, with assessments and bone marrow biopsy.

结局指标

主要结局

Feasibility Failure Rate (FFR)

时间窗: Treatment duration up to 12 cycles (28 days per cycle).

FFR is defined by the proportion of eligible subjects with higher risk CCUS who enter the study and opt to participate in the early intervention as opposed to observation only cohort.

次要结局

  • Grade 3-5 Treatment-related Toxicity Rate(AE evaluated on treatment at day 1, 8, 15, 22 on cycle 1, then day 1 on cycle 2-12, and EOT. Median treatment duration for this study cohort was 6 months (range T1- T2).)
  • Treatment Tolerability Rate (TTR)(Treatment up to 12 cycles, (28 days per cycle).)
  • Hematologic Response Rate (HRR)(Response collected every 3 months on treatment. Treatment duration up to 12 cycles, (28 days per cycle).)
  • Median Overt Myeloid Neoplasia (MN)-Free Survival(Disease evaluated every 3 months on treatment, then every 12 months off treatment, up to 2 years for interventional cohort, up to 3 years for observation cohort.)
  • Somatic Driver Mutation Variant Allele Frequencies (VAFs) Reduction Rate(Clinical next generation sequencing (NGS) is collected every 3 month on treatment, for up to 12 cycles, (28 days per cycle).)
  • Changes in Serum Inflammatory Markers(High sensitivity CRP will be measured at screening, every 6 months, and at end of study/disease progression, up to 3 years.)
  • Change in Score of the Adult Comorbidity Evaluation 27 (ACE-27)(Survey is evaluated at screening, every 6 months, and at end of study/disease progression, up to 3 years.)
  • Change in Score of the 36-item Short Form Survey (SF-36)(Survey is evaluated at screening, every 6 months, and at end of study/disease progression, up to 3 years.)

研究者

发起方
Lachelle D. Weeks, MD, PhD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Lachelle D. Weeks, MD, PhD

Sponsor-Investigator

Dana-Farber Cancer Institute

研究点 (2)

Loading locations...

相似试验

已完成
1 期
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second RelapsePatients With Multiple Myeloma Experiencing aFirst or Second Relapse
NCT01217203Innate Pharma15
招募中
不适用
Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel StudyCancer Diagnosis
NCT06523868Dana-Farber Cancer Institute1,500
Unknown
不适用
To Evaluate the Safety and Efficacy of Preemptive Administration of Continuous Renal Replacement Therapy in Patients With Acute Liver Failure With Cerebral EdemaAcute Liver Failure
NCT04991259Institute of Liver and Biliary Sciences, India60
终止
1 期
A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of ResponseOsteosarcomaLung Metastases
NCT01258634University of Chicago2
招募中
不适用
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension SystemRight Heart DysfunctionPulmonary Arterial HypertensionPulmonary Hypertension
NCT04555161Aria CV, Inc30